Acad. Ilza Pajeva, DSc | Publications

Home | CV | Publications

Publications in Journals with Impact Factor (IF)

In English:

  1. Pajeva I.K., Z.C.Lateva, and G.V.Dimitrov. BACOMP – Database of Bioactive Compounds for Structure – Activity Relationship, J. Bio-Med.Comput., 1986, 18, 7-24.  IF=0.740 (1992)
  2. Pajeva I., E.Golovinsky. Substructural Analysis of Antineoplastic Drugs in respect of in Vivo Tumor Models, Struct.-Act.Relat., 1990, 9, 216-222.  IF=1.528 (1992)
  3. Pajeva I., I. Manolov, E. Golovinsky. Structure-Activity Relationship Investigation of Bis(2-Chloroethyl)- aminoethyl Esters of Some Carboxylic Acids, Pharmazie, 1990, 45, 361-363.  IF=0.309 (1992)
  4. Dimitrov G.V., N.A.Dimitrova, K. Pajeva. The threshold stimulation and accomodation of a Hodgkin-Huxley axon, Gen.Physiol.Biophys., 1992, 11, 59-68.  IF=0.573 (1992)
  5. Pajeva I.K., D.K.Todorov. Studies of Doxorubicin in model membranes: relation to the mechanism of action and multidrug resistance, rend. Acad. bulg. Sci., 1995, 48 (11-12), 159-162.  IF =0.082 (1994)
  6. Pajeva I.K., M.Wiese, H.-P.Cordes, J.K.Seydel. Membrane interactions of some catamphiphilic drugs and relation to their multidrug resistance reversing ability, Cancer Res.Clin.Onc.,1996, 122 (1), 27-40.  IF=1.093 (1996)
  7. Pajeva I.K., M.Wiese. QSAR and molecular modelling study of multidrug resistance modifiers, Struct.-Act. Relat., 1997, 16 (1), 1-10.  IF=1.967 (1998)
  8. Wiese M., K. Pajeva: Molecular modeling study of the multidrug resistance modifiers cis- and trans-flupentixol, Pharmazie, 1997, 52 (9), 679-685.  IF=0.419 (1998)
  9. Pajeva I.K., D.K.Todorov: Study of Thaliblastine in model membranes: relation to mechanism of action and multidrug resistance, rend. Acad. bulg. Sci., 50(2), 1997, 69-72.  IF =0.082 (1994)
  10. Timcheva C., Pjeva, D.Todorov: Calcium channel blockers verapamil and diltiazem as modulators of multidrug resistance in tumours, Compt. rend. Acad. bulg. Sci., 1997, 50 (5) 137-140.  IF =0.082 (1994)
  11. Naydenova Z.L., K. Grancharov, D. Alargov, E.Golovinsky, I. Stanoeva, L. Shalamanova, Pajeva: Inhibition of UDP-glucuronosyltransferase by 5′-O-amino acid and oligopeptide derivatives of uridine: structure-activity relationships, Zeitshrift für Naturforschung, 1998, 53c, 173-181.  IF= 0.839 (1998)
  12. Pajeva I.K., M.Wiese: Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study, Med. Chem, 1998, 41, 1815-1826.  IF= 3.739 (1998)
  13. Pajeva I.K., M.Wiese: A comparative molecular field analysis of propafenone-type modulators of cancer multidrug resistance, Struct.-Act. Relat., 1998, 17, 301-312.  IF=1.967 (1998)
  14. Todorov D.K., M.V. Ilarionova, K.B. Timcheva, K. Pajeva: Antitumor activity of a Dionaea Muscipula E.preparation new in vitro and in vivo on animal and human tumors, sensitive and resistant to antitumor drugs, Biotechnol. Biotechn Eq., 12(2), 1998, 61-66.  IF= 0.029 (2002)
  15. Pajeva I., M. Wiese. Interpretation of CoMFA results – a probe set study using hydrophobic fields. Struct.-Act. Relat., 18 (4), 1999, 369-379.  IF=1.803 (1999)
  16. Todorov D.K., M. V. Ilarionova, K. Pajeva. Effectiveness of a Dionaea Muscipula E.preparation Ca-resistant tumour cells, Compt. rend. Acad. bulg. Sci., 53 (1), 2000, 129-132.  IF =0.082 (1994)
  17. Wiese M., Pajeva. Structure-activity relationships of multidrug resistance reversers, Curr. Med. Chem., 2001, 8, 685-713.  IF=5.760 (2001)
  18. Pajeva I.K., M. Wiese. Human P-glycoprotein pseudoreceptor modeling: 3D-QSAR study of thioxanthene type multidrug resistance modulators, Str.-Act. Relat., 2001, 20, 130-138.  IF =1.414 (2001)
  19. Pajeva I.K., M. Wiese. Multidrug resistance related drugs: estimation of hydrophobicity as a space directed molecular property, rend. Acad. bulg. Sci., 2001, Tome 54, 11, 81-84.  IF =0.082 (1994)
  20. Tsakovska I.M., K. Pajeva. Molecular modeling of triazine type MDR modulators using CoMFA and CoMSIA, SAR and QSAR in Environmental Research, 2002, 13(2), 1-12.  IF=1.082 (2002)
  21. Lesigiarska I., Pajeva, S. Yanev. QSAR and 3D QSAR analysis of a series of xanthates as inhibitors and inactivators of cytochrome P-450 2B1, Xenobiotica, 2002, 32 (16), 1063-1077.  IF=1.919 (2002)
  22. Pajeva I.K., M. Wiese. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (Hypothesis), Med. Chem., 2002, 45 (26), 5671-86.  IF=4.566 (2002)
  23. Tsakovska I., M. Wiese, Pajeva. Molecular modeling of phenothiazines and structurally related multidrug resistance modulators: comparative study in human and animal tumor cell lines, Biotechnol. Biotechn. Eq., 2003, 17 (2), 163-169.  IF=0.055 (2003)
  24. Pajeva I., D.K. Todorov, J.K. Seydel. Membrane effects of the antitumor drugs doxorubicin and thaliblastine: comparison to multidrug resistance modulators verapamil and trans-flupentixol, J. Pharm. Sci., 2004, 21(2-3), 243-250.  IF= 1.949 (2004)
  25. Pajeva I.K., C. Globisch, M. Wiese. Structure-Function Relationships of Multidrug Resistance P-glycoprotein, Med. Chem., 2004, 47 (10), 2523-2533.  IF= 5.076 (2004)
  26. Pajeva I.K., J.K. Seydel, D. K. Todorov. Interactions of the anticancer drugs doxorubicin and thaliblastine with model membranes and their relation to multidrug resistance, Biotechn Eq., 2004, 18 (1), 132-139.  IF=0.055 (2003)
  27. Lessigiarska I., Pajeva, M.T.D Cronin,, A.P Worth. 3D SAR and QSAR investigation of blood-brain barrier penetration of chemical compounds, SAR QSAR Environ. Res., 2005, 16, 79-91.  IF=1.753 (2005)
  28. Bogdanova S., Pajeva, P. Nikolova, I. Tsakovska, B. Müller. Interactions of poly (vinylpyrrolidone) with ibuprofen and naproxen: experimental and modeling studies, Pharmaceut. Res., 2005, 22 (5), 806-815.  IF= 2.752 (2005)
  29. Lessigiarska I., A. Nankov, A. Bocheva, Pajeva, A. Bijev. 3D-QSAR and preliminary evaluation of anti-inflammatory activity of series of N-pyrrolylcarboxilic acids, Farmaco, 2005, 60(3), 209-218.  IF = 0.790 (2002)
  30. Pajeva I., C. Globisch, R. Fleischer, I. Tsakovska, M. Wiese. Molecular modeling of P-glycoprotein and related drugs, Chem. Res., 2005, 14(2), 106-117.  IF = 0.286 (2005)
  31. Globisch C, K. Pajeva, M. Wiese. Structure-Activity Relationships of a Series of Tariquidar Analogs as Multidrug Resistance Modulators, Bioorg. Med. Chem., 2006, 14(5), 1588-1598.  IF= 2.624 (2006)
  32. Pinto-Bazurko M.M., I. Tsakovska, Pajeva. QSAR and 3D QSAR of inhibitors of the epidermal growth factor receptor, Int. J. Quant. Chem., 2006, 106 (3), 1432-1444.  IF=1.182 (2006)
  33. Tsakovska I., Pajeva. Phenothiazines and structurally related compounds as modulators of cancer multidrug resistance. Curr Drug Targets, 7, 2006, 1123-1134.  IF= 4.274 (2006)
  34. Mueller, H., W. Klinkhammer, C. Globisch, M. Kassack, I. Pajeva, Wiese: New functional assay of P-glycoprotein activity using Hoechst 33342. Bioorg. Med. Chem., 2007, 15, 7470-7479.  IF= 2.662 (2007)
  35. Globisch C., Pajeva, M. Wiese: Identification of putative binding sites of P-glycoprotein  based on its homoliogy model, ChemMedChem., 2008, 3(2), 280-295.  IF=3.150 (2008)
  36. Mueller H., Pajeva, C. Globisch, M. Wiese. Functional assay and structure-activity relationships of new 3rd generation P-glycoprotein inhibitors. Bioorg. Med. Chem., 2008, 16, 2456-2470.  IF= 3.075 (2008)
  37. Pencheva T. D. Lagorce, Pajeva, B. O. Villoutreix, M.A. Miteva. AMMOS: Automated Molecular Mechanics Optimization tool for in silico Screening, BMC Bioinformatics, 2008, 9, 438-452.  IF=3.781 (2008)
  38. Fratev F., S.O. Jonsdottir, E. Mihaylova, I. Pajeva. Molecular basis of inactive B-RAF(WT) and B-RAF(V600E) ligand inhibition, selectivity and conformational stability: an in silico Mol. Pharmaceutics, 2009, 6(1), 144-157.  IF=5.408 (2009)
  39. Klinkhammer W., H. Müller, K. Pajeva, M. Wiese. Synthesis and biological evaluation of a small molecule library of multidrug resistance modulators, Bioorg. Med. Chem., 2009, 17(6), 2524-2535.  IF = 2.822 (2009)
  40. Tsekova D.S., E. Ts. Makakova, P.S. Alov, G.A. Gorneva, K. Pajeva, L.P. Tancheva, V.V. Petkov, A.R. Surleva, B. Escuder, J. F. Miravet, E. Katz. Structure-activity relationships of new L-valine derivatives with neuropharmacological effects. Bulgarian Chemical Communications, 2009, 41(2), 133-138.  IF = 0.156 (2009)
  41. Pajeva I., M. Wiese. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. The AAPS Journal, 2009, 11 (3), 435-444.  IF = 3.540 (2009)
  42. Pajeva I., C. Globisch, M. Wiese. Combined pharmacophore modeling, docking and 3D QSAR study of ABCB1 and ABCC1 transporter inhibitors. ChemMedChem, 2009, 4 (11), 1883-1896.  IF = 3.232 (2009)
  43. Pajeva I.K. Book review of “Structural Bioinformatics: An Algorithmic Approach” by Forbes J. Burkowski, BioMedical Engineering On Line, 2009, 8-14.  IF=1.639 (2009)
    43а.     Published also in: Virtual Issue Ion Channels and Transporters of FEBS journal, 2010
  44. Pajeva I., C. Globisch, M. Wiese. Comparison of the inward- and outward-open homology models and ligand binding of human P-glycoprotein. FEBS J., 2009, 276 (23), 7016–7026.  IF = 3.042 (2009)
  45. Pencheva T., O.S, Soumana, Pajeva , M.A. Miteva. Post-docking virtual screening of diverse binding pockets: Comparative study using DOCK, AMMOS, X-Score and FRED scoring functions. Eur J Med Chem., 2010, 45, 2622–2628.  IF=3.193 (2010)
  46. Tsakovska I., Pajeva, P. Alov, A. Worth. Recent advances in the molecular modelling of estrogen receptor-mediated toxicity. Adv Protein Chem Struct Biol. 2011, 85, 217-251.  IF=1.833 (2011)
  47. Pick A., H. Müller, R. Mayer, B. Haenisch, K. Pajeva, M. Weight, H. Bönisch, C. E. Müller, M. Wiese. Structure-Activity Relationships of Flavonoids ss Inhibitors of Breast Cancer Resistance Protein (BCRP). Bioorg. Med. Chem., 2011, 19(6), 2090-2102.  IF=2.921 (2011)
  48. Lessigiarska I., Pajeva, P. Prodanova, M. Georgieva, A. Bijev. Structure-activity relationships of pyrrole hydrazones as new anti-tuberculosis agents. Medicinal Chemistry, 2012, 8 (3), 462-473.  IF=1.373 (2012)
  49. Jereva D., Pajeva, T. Pencheva. Data extraction module – a supplementary tool for AMMOS_ ProtLig software package. Comput. Math. Appl., 2012, 64 (3), 266-271.  IF=2.069 (2012)
  50. Pencheva T., D. Jereva, M. Miteva, Pajeva. Post-docking Optimization and Analysis of Protein-Ligand Interactions of Estrogen Receptor Alpha using AMMOS Software. Current Computer-Aided Drug Design, 2013, 9 (1), 83-94.  IF=1.942 (2013)
  51. Fratev F, SO Jónsdóttir, Pajeva. Structural insight into the UNC-45-Myosin complex. Proteins-Structure Function and Bioinformatics, 2013, 81(7), 1212-1221.  IF=2.921 (2013)
  52. Pajeva I. , M. Hanl, M. Wiese. Protein contacts and ligand binding in the inward-facing model of human P-glycoprotein, ChemMedChem., 2013, 8 (5), 748–762.  IF=3.046 (2013)
  53. Pajeva I., K. Sterz, K. Steggemann, F. Marighetti, M. Christlieb, M. Wiese. Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogs with P-glycoprotein. ChemMedChem., 2013, 8 (10), 1701–1713.  IF= 3.046 (2013)
  54. Al Sharif M., P. Alov, V. Vitcheva, Pajeva, I. Tsakovska. Modes-of-action related to repeated dose toxicity: tissue-specific biological roles of PPARγ ligand-dependent dysregulation in nonalcoholic fatty liver disease, PPAR research, 2014, Article ID 432647, 13 pages.  IF=2.509 (2014)
  55. Wiese M., Pajeva. HAGE, the helicase antigen as a biomarker for breast cancer prognosis (WO2013144616). Expert Opin. Ther. Pat., 2014, 24(6), 723-725.  IF=4.297(2014)
  56. Fratev F., Е. Mihaylova, Pajeva. Combination of genetic screen and molecular dynamics as a useful tool for identification of diseases-related mutations: ZASP PDZ domain G54S mutation case. J. Chem. Inf. Model., 2014, 54(5), 1524-1536.  IF=3.738 (2014)
  57. Tsakovska I., M. Al Sharif, P. Alov, A. Diukendjieva, E. Fioravanzo, M.T.D. Cronin, Pajeva. Molecular modelling study of PPARγ receptor in relation to the mode of action / adverse outcome pathway framework for liver steatosis. Int. J. Mol. Sci., 2014, 15, 7651-7666.  IF=2.862 (2014)
  58. Tzvetkov N.T., Pajeva. Binding and interactions of a novel potent indole-5-carboxamide MAO-B inhibitor. Compt. rend. Acad. bulg. Sci., 2014, Tom 67, No.7, 937-942.  IF=0.0.307 (2014)
  59. Alov O., I. Tsakovska, Pajeva. Computational Studies of Free Radical-Scavenging Properties of Phenolic Compounds. Current Topics in Medicinal Chemistry, 2015, 15(2), 85-104. IF=2.900 (2015)
  60. Fratev F., I. Tsakovska, M.Al Sharif, E. Mihaylova, Pajeva. Structural and Dynamical Insight into PPARγ Antagonism: In SilicoStudy of the Ligand-Receptor Interactions of Non-Covalent Antagonists. Int. J.Mol. Sci,. 2015, 16 (7), 15405-15424. IF=3.257 (2015)
  61. Alov P., I. Tsakovska, Pajeva. Quantitative structure-property relationship modelling of antiradical properties of natural polyphenols using EVA vector descriptor approach. Comptes rendus de l’Academie bulgare des Sciences, 69 (9), 2016, 1145-1152. IF=0.251 (2016)
  62. Diukendjieva , M. Al Sharif, P. Alov, T. Pencheva, I. Tsakovska, I. Pajeva. ADME/Tox Properties and Biochemical interactions of Silybin Congeners: In Silico Study. Natural Product Communications, 2017, 12 (2), 175-178. IF = 0.809 (2017)
  63. Al Sharif M., I. Tsakovska, Pajeva, P. Alov, E. Fioravanzo, A. Bassan, S. Kovarich, C. Yang, A. Mostrag-Szlichtyng, V. Vitcheva, A. P. Worth, A. N. Richarz, M.T. D. Cronin. The Application of Molecular Modelling in the Safety Assessment of Chemicals: A Case Study on Ligand-Dependent PPARγ Dysregulation, Toxicology, 2017, 392, 140-154. doi:10.1016/j.tox.2016.01.009. IF=3.265 (2017)
  64. Jereva D., F. Fratev, I. Tsakovska, P. Alov, T. Pencheva, Pajeva. Molecular Dynamics Simulation of the Human Estrogen Receptor Alpha: Contribution to the Pharmacophore of the Agonists. Mathematics and Computers in Simulation, 2017, 133 (C), 124-134. IF=1.476 (2017)
  65. Labbé C., Pencheva, D. Jereva, D. Desvillechabrol, J. Becot, B.O. Villoutreix, I. Pajeva, M. Miteva. AMMOS2: a web server for protein-ligand-water complexes refinement via molecular mechanics, Nucleic Acids Research, 2017, 45 (W1), W350–W355. IF = 11.561 (2017)
  66. Tsakovska I., Pajeva, M. Al Sharif, P. Alov, E. Fioravanzo, S. Kovarich, A. P. Worth, A. Richarz, C. Yang, A. Mostrag-Szlichtyng, M.T.D. Cronin. Quantitative structure − skin permeability relationships. Review Article, Toxicology, 2017, 387, 27-42. IF = 3.265 (2017)
  67. Stoyanova T., I. Lessigiarska, M. Mikov, Pajeva, S. Yanev,. Xanthates as useful probes for testing the active sites of Cytochromes P450 4A11 and 2E1. Frontiers in Pharmacology, 8, 2017, Article 672. IF=3.831 (2017)
  68. Al Sharif M., A. Diukendjieva-Todorova, P. Alov, V. Vitcheva, M. Mori, B. Botta, I. Tsakovska, Pajeva. Natural modulators of nonalcoholic fatty liver disease: mode of action analysis and in silico ADMET prediction, Toxicology and Applied Pharmacology, 2017, 337, 45-66. IF = 3.616 (2017)
  69. Al Sharif M., P. Alov, A. Diukendjieva, V. Vitcheva; R. Simeonova, I. Krasteva, A. Shkondrov, I. Tsakovska, Pajeva. Molecular determinants of PPARγ partial agonism and related in silico / in vivo studies of natural saponins as potential type 2 diabetes modulators, Food and Chemical Toxicology, 2018, 112, 47-59. IF = 3.3775 (2018)
  70. Diukendjieva A., P. Alov, I. Tsakovska, T. Pencheva, A. Richarz, V. Kren, T.D. Cronin, I. Pajeva. In vitro and in silico studies of the membrane permeability of natural flavonoids from Silybum marianum (L.) Gaertn. and their derivatives, Phytomedicine, 2019, 53, 79-85. IF =  4.180 (2018)
  71. Al Sharif M., V. Vitcheva, R. Simeonova, I. Krasteva, V. Manov, P. Alov, G. Popov, A. Shkondrov, Pajeva. In silico and in vivo studies of Astragalus glycyphylloides saponin(s) with potential relevance to metabolic syndrome modulation, Food and Chemical Toxicology, 2019, 130, 317-325. IF = 4.679 (2019)
  72. Lagarde, E. Goldwaser, T. Pencheva, D. Jereva, I. Pajeva, J. Rey, P. Tuffery, B.O. Villoutreix, M.A. Miteva. A free web-based protocol to assist structure-based virtual screening experiments. International Journal of Molecular Sciences, 2019, 20 (18), 4648. IF=4.556 ( 2019)
  73. Dinić J., A. Podolski-Renić, M. Jovanović, L. Musso, I. Tsakovska, I. Pajeva, S. Dallavalle, M. Pešić. Novel Heat Shock Protein 90 inhibitors suppress P-glycoprotein activity and overcome multidrug resistance in cancer cells. International Journal of Molecular Sciences (ISSN 1422-0067). Special Issue “Molecular Chaperones 2.0”, 2019, 20, 4575. IF=4.556 ( 2019)
  74. Dallavalle S.; V. Dobričić; L. Lazzarato; E. Gazzano; M. Machucheiroe, I. Pajeva; I. Tsakovska, N. Zidar; R. Fruttero. Improvement of Conventional Anti-Cancer Drugs as New Tools against Resistant Tumors, Drug Resistance Update, 2020, 50, 100682. IF=11.000 (2019)
    IF= 18.5 (2020)
    in the top 1% of cited papers in the field according to Web of Science
  75. Diukendjieva ,  M. Zaharieva, M. Mori, P. Alov, I. Tsakovska, T. Pencheva, H. Najdenski, V. Kren, C. Felici, F. Bufalieri, L. Di Marcotullio, B. Botta, M. Botta, I. Pajeva. Dual Smo/BRAF inhibition by flavonolignans from Silybum marianum. Antioxidants, 2020, 9(5), 384, 13 pages. IF=6.312 (2020)
  76. Dinić J., T. Efferth, A.T. García-Sosa, J. Grahovac, J. M. Padrón, I. Pajeva, F. Rizzolio, S. Saponara, G. Spengler, I. Tsakovska, Repurposing old drugs to fight multidrug resistant cancers, Drug Resistance Updates, Volume 52, 2020, 100713. IF=18.5 (2020)
  77. Ilieva Y., L. Dimitrova, M.M.Zaharieva, M. Kaleva, P. Alov, I. Tsakovska, T. Pencheva, I. Pencheva-El Tibi, H. Najdenski, I. Pajeva. Cytotoxicity and microbicidal activity of commonly used organic solvents: a comparative study and application to a standardized extract from Vaccinium Macrocarpon, Toxics, 2021, 9, 92. DOI:10.3390/toxics9050092 IF = 4.146 (2020)
  78. Lessigiarska, I.; Peng, Y.; Tsakovska, I.; Alov, P.; Lagarde, N.; Jereva, D.; Villoutreix, B.O.; Nicot, A.B.; Pajeva, I.; Pencheva, T.; Miteva, M.A. Computational Analysis of Chemical Space of Natural Compounds Interacting with Sulfotransferases. Molecules, 2021, 26, 6360. DOI:10.3390/molecules26216360 IF = 4.927 (2021)
  79. Podolski-Renić, A.; Dinić, J.; Stanković, T.; Tsakovska, I.; Pajeva, I.; Tuccinardi, T.; Botta, L.; Schenone, S.; Pešić, M. New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-d]Pyrimidine Tyrosine Kinase Inhibitors. Cancers, 2021, 13, 5308. DOI:10.3390/cancers13215308 IF=6.575 (2021)
  80. Alov P., M. Al Sharif, D. Aluani, K. Chegaev, J. Dinic, A. Divac Rankov, M.X. Fernandes, F. Fusi, A.T. García-Sosa, R.O. Juvonen, M. Kondeva-Burdina, J.M. Padrón, Pajeva, T. Pencheva, A. Puerta, H. Raunio, C. Riganti, I. Tsakovska, V. Tzankova, Y. Yordanov, S. Saponara. A comprehensive evaluation of Sdox, a promising H2S-releasing doxorubicin for the treatment of chemoresistant tumors”. Frontiers in Pharmacology, 2022, 13, Article 831791. DOI:10.3389/fphar.2022.831791 IF=5.988 (2021)
  81. Tzvetkov, N.T.; Peeva, M.; Tsakovska, I.; Milella, L; Pajeva, I.; Stammler, H-G. The crystal structure of (4SR)-7-(3,4-dichlorobenzyl)-4,8,8-trimethyl-7,8-dihydroimidazo[5,1c] [1,2,4]triazine-3,6(2H,4H)-dione, C15H16Cl2N4O2. Zeitschrift für Kristallographie – New Crystal Structures, 2022, vol. 237, no. 2, pp. 319-321. DOI:10.1515/ncrs-2022-0016 IF = 0.365 (2021)
  82. Alov, P.; Tsakovska, I.; Pajeva, I. Hybrid Classification/Regression Approach to QSAR Modeling of Stoichiometric Antiradical Capacity Assays’ Endpoints. Molecules, 2022, 27, 2084. DOI:10.3390/molecules27072084 IF = 4.927 (2021)
  83. Alov, P.; Al Sharif, M.; Najdenski, H.; Pencheva, T.; Tsakovska, I.; Zaharieva, M.M.; Pajeva, I. New Potential Pharmacological Targets of Plant-Derived Hydroxyanthra-quinones from RubiaMolecules 2022, 27, 3274. DOI:10.3390/molecules27103274 IF = 4.927 (2021)
  84. Jereva, D.; Alov, P.; Tsakovska, I.; Angelova, M.; Atanassova, V.; Vassilev, P.; Ikonomov, N.; Atanassov, K.; Pajeva, I.; Pencheva, T. Application of InterCriteria Analysis to Assess the Performance of Scoring Functions in Molecular Docking Software Packages. Mathematics 2022, 10, 2549. DOI:10.3390/math10152549I IF = 2.592 (2021)
  85. Alov, P.; Stoimenov, H.; Lessigiarska, I.; Pencheva, T.; Tzvetkov, N.T.; Pajeva, I.; Tsakovska, I. In Silico Identification of Multi-Target Ligands as Promising Hit Compounds for Neurodegenerative Diseases Drug Development. Int. J. Mol. Sci. 2022, 23, 13650. DOI:10.3390/ijms232113650 IF = 6.208 (2021)
  86. Vezenkov, L.T.; D.S. Tsekova; I. Kostadinova; R. Mihaylova; V. Lozanov; N.G. Vassilev; N. Danchev; I. Tsakovska; I. Pajeva. Synthesis and Biological Study of 4-Aminopyridine-Peptide Derivatives Designed for the Treatment of Neurodegenerative Disorders. Current Alzheimer Research, 2023, 20 (2), 120-129, https://doi.org/10.2174/1567205020666230602142012 IF= 2.1 (2022)
  87. Angelova, V.T.; Georgiev, B.; Pencheva, T.; Pajeva, I.; Rangelov, M.; Todorova, N.; Zheleva-Dimitrova, D.; Kalcheva-Yovkova, E.; Valkova, I.V.; Vassilev, N.; Mihaylova R., Stefanova D., Petrov B., Voynikov Y., Tzankova V. Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer’s Disease. Pharmaceuticals 2023, 16, 1194. https://doi.org/10.3390/ph16091194

In Russian:

  1. Павлова  Й.Р., И.К. Пъжева, Г.Д. Велинов, О.Е. Будевски. Метод количественного определения содержания серной и фосфорной кислот в смеси, Журн. прикл. хим., 1981, LIV, 1946-1949.  IF=0.065

Publications in journals and thematic series with SCImago Journal Rank (SJR):

  1. (1) Tsakovska, I., M. Pinto-Bazurco, I. Pajeva: Receptor tyrosine kinase inhibitors: QSAR and molecular modelling study, Pharmatsija, 2005, 52 (3), 11-15. SJR=0.101 (2005)
  2. (2) Al Sharif M., A. Diukendjieva, P. Alov, Richards, M.T.D. Cronin, I. Tsakovska, I. Pajeva. Optimized structure – based methodology for studying PPARγ partial agonists. Int.J. BIOautomation, 2018, 22 (1), 65-72. DOI:10.7546/ijba.2018.22.1 SJR=0.267 (2018)
  3. (3) Diukendjieva A., I. Tsakovska, P. Alov, T. Pencheva, I. Pajeva, A. Worth, J. Madden, M.T.D. Cronin. Advances in the Prediction of Gastrointestinal Absorption: Quantitative Structure-Activity Relationship (QSAR) modelling of PAMPA Permeability. Computational Toxicology, 2019, 10, 51-59. DOI:10.1016/j.comtox.2018.12.008 SJR=0.579 (2019)
  4. (4) Jereva, T. Pencheva, I. Tsakovska, P. Alov, I. Pajeva. Exploring Appicability of InterCriteria Analysis on the Performance of MOE and GOLD Scoring Functions. In: I. Georgiev et al. (eds.) Advanced Computing in Industrial Mathematics, Studies in Computational Intelligence, Springer, 2021, vol. 961, 198-208. DOI: 10.1007/978-3-030-71616-5_18  SJR=0.185 (2020)
  5. (5) Tsakovska I., P. Alov, N. Ikonomov, V. Atanassova, P. Vassilev, O. Roeva, D. Jereva, K. Atanassov, Pajeva, T. Pencheva. InterCriteria Analysis Implementation for Exploration of the Performance of Various Docking Scoring Functions. In: Dimov I., Fidanova S. (eds) Advances in High Performance Computing. HPC 2019. Studies in Computational Intelligence, 2021, vol. 902, 88-98. DOI: 10.1007/978-3-030-55347-0_8 SJR=0.185 (2020)
  6. (6) Al Sharif M. P. Alov, V. Vitcheva, A. Diukendjieva, D. Aluani, V. Tzankova, Pajeva. Development of a Protocol for Virtual Screening of PPARγ Weak Partial Agonists: Case Study on Naturally-Derived Oleanane Triterpenoids, Int. J. BIOautomation, 2021, 25 (2), 117-132. SJR=0.178 (2020)
  7. (7) Jereva D., M. Angelova, I. Tsakovska, P. Alov, I. Pajeva, M. Miteva. InterCriteria Analysis Approach for Decision-Making in Virtual Screening: Comparative Study of Various Scoring Functions. In: Sotirov S.S., Pencheva T., Kacprzyk J., Atanassov K.T., Sotirova E., Staneva G. (eds) Contemporary Methods in Bioinformatics and Biomedicine and Their Applications. BioInfoMed 2020. Lecture Notes in Networks and Systems, Springer, Cham, 2022, vol. 374, pp. 67-78. DOI:10.1007/978-3-030-96638-6_8 SJR=0.151 (2021)
  8. (8) Dessislava Jereva, Maria Angelova, Ivanka Tsakovska, Petko Alov, Ilza Pajeva, Maria Miteva, Tania Pencheva, An Application of InterCriteria Analysis Approach to Assess the AMMOS Software Platform Outcomes, Biomath, 2022, 11, 2203068. DOI:10.55630/j.biomath.2022.03.068 SJR = 0.246 (2021)
  9. (9) Alov, P., Pajeva, I., Tsakovska, I., Pencheva, T. Comparison of Docking Scoring Functions by InterCriteria Analysis on a Set of Protein Targets Related to Alzheimer and Parkinson Diseases. In: Sotirov, S., Pencheva, T., Kacprzyk, J., Atanassov, K.T., Sotirova, E., Ribagin, S. (eds) Recent Contributions to Bioinformatics and Biomedical Sciences and Engineering. BioInfoMed 2022. Lecture Notes in Networks and Systems, 2023, vol. 658, 98-110. Springer, Cham. https://doi.org/10.1007/978-3-031-31069-0_11
    SJR=0.15 (2022)

Publications in Peer-Reviewed Journals without IF or SJR

In international and foreign periodicals:

  1. (1) Pajeva, I. K., J.K.Seydel, L.Bock: Study of interactions between phospholipids and amphiphilic drugs active in reversing multidrug resistance in tumour cells, Jahresbericht 1993, Forschungszentrum Borstel, C.H.Waser, 1994, 138-142.
  2. (2) Timcheva, C., I. Pajeva, D.Todorov, E.Pipercova, I.Triphonova: Calcium channel blocker diltiazem as MDR-modulator, J. Balkan Union of Oncology, 2, 1996, 31-35.
  3. (3) Pajeva, I.K., C. Globisch, R. Fleischer, M. Wiese: Structure-function relationships of P-glycoprotein and related drugs: molecular modeling study, Actualites de Chimie Therapeutique, 2005, 31e serie, 167-180.
  4. (4) Tsakovska, I., I. Lessigiarska, T. Netzeva, Pajeva, A. Worth: Review of quantitative structure – activity relationships for acute mammalian toxicity, Int. J. Bioautomation, 2006, 5, 90-105.
  5. (5) Pencheva, T., D. Lagorce, Pajeva, B. Villoutreix, M. Miteva. AMMOS: A Software Platform for in silico Screening., Int. J. Bioautomation, 2009, 13(4), 143-150.
  6. (6) Jereva D., T. Pencheva, D. Lagorce, D. Desvillechabrol, Pajeva, M. Miteva. Post-docking optimization of protein-ligand interactions involving water molecules. Asian Journal of Physics: Biophysics, Bioinformatics & Physical Methods in Biology and Medicine (а special issue), 2014, 23 (5), 745-756.

In Bulgarian periodicals:

  1. (1) Павлова,Й., И. Пъжева: Текуща идентификация на сложни химико-технологични обекти по метода на стохастическата апроксимация, Годишник на ЦЛА при МХП, 1979, IV, част II, 9-15.
  2. (2) Илиева,Е., Й.Павлова, И. Пъжева: Изследване на чувствителността на моделите, описващи процесите в дестилационна колона в содово производство, Годишник на ЦЛА при МХП, 1980, V, 9-20.
  3. (3) Павлова,Й., И. Пъжева, Г.Велинов: Нов подход при анализ на вещества с киселинно-основни свойства, Годишник на ЦЛА при МХП, 1980, V, 147-151.
  4. (4) Латева,З.Х., И.К. Пъжева: Модел на информационни структури за изследване на връзката между химическа структура и биологическа активност с помощта на ЕИМ,  Фармация, 1984, XXXIV,  5, 39-45.
  5. (5) Пъжева, И.: Система за прогнозиране на противотуморна активност на съединения спрямо туморни модели  in vivo, Онкология, 1989, XXVI, 1, 26-29.
  6. (6) Тодоров, Д.К., К. Тимчева, И. Пъжева: Лекарствена резистентност при злокачествени тумори и подходи за преодоляването и, Онкология, 1995, 32 (3-4), 9-13.
  7. (7) Тимчева, K., И. Пъжева, Д.K. Тодоров: Лекарствена резистентност на туморите – същност, клинично значение, преодоляване, Фармакотерапия, 1996, 2 (2),15-20.
  8. (8) Пъжева, И.К., Л.Д.Шаламанова, И.М.Станоева: Зависимостите структура-активност при изследване на противотуморни лекарства – основни подходи и приложение, Онкологичен преглед, 1996, III, 3-4, 10-14.
  9. (9) Станоева, И.М., Л.Д.Шаламанова, Пъжева, И.К.: Подходи на молекулното моделиране в изследванията съединения с противотуморна активност, Онкологичен преглед, 1997, IV (3), 19-24.
  10. (10) Тодоров, Д., К.Тимчева, И.Пъжевa: Лекарствена резистентност при рака, Съвременна медицина, 1997, XLVIII, 4, 3-7.
  11. (11) Атанасов,К., Л.Вайсберг, K.Гарсия, М.Даскалов, И.Пъжева, Р.Струб, А.Шенон, Й. Шоршич: Обобщени мрежи в биологията и медицината, Списание на БАН, 1998, CX1, 1-2, 44-49.
  12. (12) Тимчева,К., И. Пъжева, Д.Тодоров: Лекарствена резистентност при злокачествени тумори – фундаментални и клинични аспекти, Studia Onciologia, 2000, I (1), 9-27.
  13. (13) Лесигярска, И., И. Пъжева, Б. Пандова, С. Янев: QSAR и 3D QSAR анализ на серия акилксантати като инхибитори и инактиватори на цитохром P-450 2B1, в: Научни известия на Научно-техническия съюз по машиностроене, 2000, год. VII, 3(54), 150-155.
  14. (14) Пъжева, И., И. Цаковска, Т. Пенчева, П. Алов, И. Лесигярска: Изследване на зависимости “структура-активност” и молекулно моделиране на биологично активни съединения. Списание на БАН, 2009, 2, 41-47.
  15. (15) Пъжева, И., И. Цаковска, Т. Пенчева, П. Алов, М. Ал Шариф, И. Лесигярска, Ф. Фратев, Д. Жерева, А. Дюкенджиева. In silico изследвания на биологично активни молекули, Списание на БАН, 4, 2018, 3-10.
  16. (16) Al Sharif M., P. Alov, I. Tsakovska, T. Pencheva, I. Pajeva. Estimation of structural similarity between plant-derived phenolic compounds and drug molecules by virtual screening of DrugBank, International Scientific Journal “Machines. Technologies. Materials”, XIV (2), 2020, 83-86.  https://stumejournals.com/journals/mtm/2020/2/83 (отпечатано и в сборник от доклади на конференция)

Publications in Books and Thematic Series

Published abroad:

  1. (1) Pajeva, I.K., Z.C. Lateva, G.V. Dimitrov: SAR Oriented Database Aids Selection of Compounds for Screening, In: Pharmacochemistry Library, Vol.10, QSAR in Drug Design and Toxicology, D. Hadzi and B. Jerman‑Blazic (Eds.), Elsevier, Amsterdam, 1987, 49‑51. ISBN 0-444-42767-8
  2. (2) Pajeva,I.K.: Antineoplastic Activity Prediction by means of a Statistical‑Heuristic Technique, In: Progress in Clinical and Biological Research, Vol.291, QSAR: Quantitative Structure ‑ Activity Relationships in Drug Design,L.Fauchere (Ed.), Alan R. Liss, Inc., New York, 1989, 209‑212. ISBN 0-8451-5141-X
  3. (3) Pajeva, I.K., N.M. Neykov, P.N. Neytchev: Application of a Robust Method for Detecting Outliers in Data Used for Antineoplastic Activity Prediction, In: Trends in QSAR and Molecular Modelling 92, C.G.Wermuth (Ed.), Escom, Leiden, 1993, 324-325. ISBN 10: 9072199138
  4. (4) Pajeva, I.K., J.K. Seydel: Drug-membrane interactions of some catamphiphiles: relation to the reversal of multidrug resistance in tumour cells. Pharmazie in Unsere Zeit, 1994, 23 (3), 178 (Tagung der Fachgruppe Pharmazeutische Chemie der Deutschen Pharmazeutischen Gesellshaft, 7-9 March 1994, Mainz, Germany).
  5. (5) Pajeva, I.K., J.K. Seydel, M. Wiese: Drug-Membrane Interactions: Relationships with Multidrug Resistance Reversing Activity in Tumour Cells, In: QSAR and Molecular Modelling: Computational Tools and Bilogical Applications, F.Sanz, J. Giraldo, F.Manaut (Eds.), Prous Science Publishers, 1995, 131-133. ISBN 84-8124-079-6
  6. (6) Wiese, M., K.Pajeva: Comparative molecular field analysis of modulators of cancer multidrug resistance, In: CHEMOMETRICS V, J. Havel (ed.), 1999, Masaryk University, Brno, p.I61-63.
  7. (7) Pajeva, I.K., M. Wiese: Comparative molecular field analysis of multidrug resistance modifiers, In: Molecular Modeling and Prediction of Bioactivity, K. Gundertofte and F.S. Jorgensen (Eds.), Kluwer Academic / Plenum Publishers, New York, 2000, 414-416. ISBN 0-306-46217-6
  8. (8) Pajeva, I.K., M. Wiese: Hydrophobic “dipole”: space directionality of hydrophobicity of multidrug resistance inducers and modulators, In: “Lipophilicity in Drug Disposition”, -A. Carrupt, S. Rey (Eds.), “Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies. Wiley-VCH, Weinheim, 2001, Pb04. ISBN 3-906390-22-5.
  9. (9) Pajeva, I. K., Globisch, C., Fleischer, R., Tsakovska, I., M. Wiese: Molecular modeling of P-glycoprotein and related drugs, Internatl. on Current Trends in Drug Discovery Research (CTDDR-2004), 17-20 Feb 2004, Lucknow, India, 214-215.
  10. (10) Pajeva, I., M. Wiese: Modeling of interactions with the multidrug resistance transporter P-glycoprotein, Proceedings of 8th International Symposium on Pharmaceutical Sciences (ISOPS-8), Ankara, Turkey, 13-18 June 2006, 61-63.
  11. (11) Kacprzyk1, Janusz, M. Angelova,P. Vassilev,V. Tasseva, P. Tchesmedjiev, I. Pajeva, K. Atanassov: On the Modelling of Genetic Networks with Generalized Nets, In: “Issues in intuitionisctic fuzzy sets and generalized nets” . K. Atanassov, J. Kacprzyk, M. Krawczak, E. Szmidt  (Eds.), 2007, Vol. 5, Warsaw school of information technology, Warsaw, 87-96. ISBN 978-83-88311-90-1
  12. (12) Tsekova, D., L. Tancheva, E. Makakova, P. Alov, I. Pajeva, V. Petkov. In-vivo and in-vitro activities of new L-Valine derivatives: structure-activity relationships, Proceedings of the 30th European Peptide Symposium (30EPS), Helsinki, Finlandia, 2008, 224-225.
  13. (13) Pajeva, I. Zeit – abhängig Präsentationen der Wechselwirkungen von Arzneistoffen In: Phänomen Zeit: Dimensionen und Strukturen in Kultur und Wissenschaft (Dietmar Goltschnigg, Hrsg.), Stauffenburg Verlag, 2011, 307-308. ISBN-10: 3860570242
  14. (14) Fioravanzo E., A. Bassan, S. Kovarich, I. Tsakovska, I. Pajeva, A. Palczewska, V. Vitcheva, M.T.D. Cronin, C. Yang, A. Worth. Use of Molecular Modelling Approaches to Predict Potential Binding to Nuclear Receptors Involved in the Development of Liver Steatosis (i.e. LXR and PPARγ). In: Mechanism-Based Methods for Improved Toxicity Testing (Timan Gocht and Michael Schwarz, eds.), 2015, Vol. 5, 83-85. ISBN: 978-2-9539634-4-1

Published in Bulgaria:

  1. (1) Pajeva, I., I. Tsakovska: Structure-activity relationships and molecular modeling of multidrug resistance modifiers, In: Current trends in the development of fundamental and applied sciences, N. Lazarov, L. Lazarov, K. Halacheva (eds.), vol.2, 1999, p.76-82. ISBN 954-9794-14-8
  2. (2) Tsakovska, I., Pajeva: Molecular modeling of new triazine derivatives as modulators of multidrug resistance, In: Current trends in the development of fundamental and applied sciences, N. Lazarov, L. Lazarov, K. Halacheva (eds.), vol.2, 1999, p.83-90. ISBN 954-9794-14-8
  3. (3) Lesigiarska I., Pajeva: QSAR and 3D QSAR in drug design: cytochrome P-450 inhibitors and antiinflammatory agents, in: Biprocess Systems’ 2001, Proceedings of 14th International. Symposium and Young Scientists’ School, October 1-3 2001, Sofia, Bulgaria, 2001, A: 17-20.
  4. (4) Tsakovska I., L. Shalalmanova, Pajeva: QSAR and molecular modeling study of phenothiazines and structurally related compounds as multidrug resistance modulators, in: Biprocess Systems’ 2001, Proceedings of 14th International. Symposium and Young Scientists’ School, Oct 1-3 2001, Sofia, Bulgaria, III, 2001, 27-30.
  5. (5) Pencheva T., I. Pajeva, M. Comparative Study of Different Scoring Functions for Virtual Ligand Screening, Proceedings of International Symposium “Bioprocess Systems‘2008 – BioPS’08”, Sofia, Bulgaria, November 4-5, 2008, II.89 – II.100.
  6. (6) Pencheva T., P. Alov, D. Jereva, Pajeva, M. A. Miteva. Post-docking Optimization and Analysis of Protein-ligand Interactions with AMMOS Free Software. In: Topics In Chemistry And Material Science (Eds. R.D. Nikolova, S. Simova, P. Denkova, G.N. Vayssilov), Vol. 5, Current Issues in Organic Chemistry 2,  2011,  43–51. ISSN 1314-0795
  7. (7) Al Sharif M, Alov P, I. Tsakovska, I. Pajeva. In silico modelling of full PPARγ agonists: a step towards liver steatosis risk assessment. Series G. Medicine, Pharmacy and Dental medicine, Union of Scientists in Bulgaria – Plovdiv,  Vol. XVII, p. 182-186, 2015. ISSN 1311-9427
  8. (8) Diukendjieva, L. Marinov, P. Alov, I. Tsakovska, I. Pajeva. In silico modelling to predict transcellular permeability of bioactive compounds. Series G. Medicine, Pharmacy and Dental medicine, Union of Scientists in Bulgaria – Plovdiv, Vol. XVII, p. 187-190, 2015. ISSN 1311-9427
  9. (9) Diukendjieva, A., M. Al Sharif, I. Tsakovska, T. Pencheva, P. Alov, Pajeva. In silico study of natural compounds: prediction of metabolism, toxicity and biochemical interactions. In: Scientific reports (Eds. R. Argirova, D. Boteva, Y. Kalvachev), Faber Publishing House, 2018, 24-33. ISBN 978-61900-0827-9
  10. (10) Al Sharif M., P. Alov, I. Tsakovska, T. Pencheva, I. Pajeva, Estimation of structural similarity between plant-derived phenolic compounds and drug molecules by virtual screening of DrugBank, V-th International conference high technology. Business. Society 2020, 09-12.03.2020 – Borovets, Bulgaria, Proceedings, Year V, Issue 1 (7), Sofia, Bulgaria 2020, 21-24. ISSN 2535-0005

Monograph

  1. Wiese, M., I. Pajeva: In silico models for interactions with transporters. In: Comprehensive Medicinal Chemistry II, (Editors-in-Chief: John B Taylor and David J Triggle) Vol. 5: ADMET/Property based approaches, (Eds. B. Testa, H. Waterbeemed), In silico tools in ADMET, Elsevier: Oxford, 2007, 767-795. ISBN: 978-0-08-045044-5

Book Chapters, incl. with SJR

  1. (1) Seydel, J.K., E.A. Coats, I.K. Pajeva, M. Wiese: Drug-membrane interaction and accumulation, conformation, efficacy and resistance, In: Bioactive Compound Design: Possibilities for Industrial Use, M.G. Ford, R. Greenwood, G.T. Brooks, R. Franke (Eds.) SCI, BIOS Sci. Publ. Ltd., Oxford, 1996, 137-147. ISBN 1859961657
  2. (2) Wiese, M., Pajeva. Algorithms to predict affinity for transporters, In: Virtual ADMET assessment in target selection and maturation, Solvay Pharmaceuticals Conferences Series (vol. 6), B. Testa, L. Turski (Eds.), IOS Press, Amsterdam, 2006, 187-208. ISBN 978-1-58603-703-1
  3. (3) Pajeva, I., M. Wiese. Application of In silico Methods to Study ABC Transporters Involved in Multidrug Resistance. In: In silico Lead Discovery ( A. Miteva, Ed.),  Bentham Science, 2010, Vol. 1, 144-162. eISBN: 978-1-60805-142-7
  4. (4) Pencheva, T., D. Lagorce, Pajeva, B. O. Villoutreix, M. A. Miteva, AMMOS Software: Method and Application. In: Computational Drug Discovery and Design (Methods Mol. Biol.) R. Baron (Ed.), Humana Press, 2012, 819, 127-141. ISBN-10: 1617794643 SJR=0.753 (2012)
  5. (5) Martiny, , I. Pajeva, M. Wiese, A.M. Davis, M. A. Miteva. Chemoinformatic and chemogenomic approach to ADMET. Chapter 5, Part II: Intelligent integration and extrapolation of ADMET data, In: Predictive ADMET: Integrated approaches in drug discovery and development (Eds. J. Wang and L. Urban), John Wiley & Sons, Inc., 2014, 125-144. ISBN: 978-1-118-29992-0
  6. (6) Al Sharif, M., I. Tsakovska, P. Alov, V. Vitcheva, A. Diukendjieva, I. Pajeva. Molecular modeling approach to study the PPARγ-ligand interactions. Methods in Molecular Biology, Humana, New York, NY, 2019, 1966: 261-289. DOI:1007/978-1-4939-9195-2_22. ISBN: 978-1-4939-9195-2 SJR=0.597 (2019)
  7. (7) Pajeva I., I. Tsakovska, T. Pencheva, P. Alov, M. Al Sharif, I. Lesigiarska, D. Jereva, A. Diukendjieva. In silico studies of biоlogically active molecules. In: Research in Computer Science in the Bulgarian Academy of Sciences (Ed. K. Atanassov), Book series: Studies in Computational Intelligence (Ed. J. Kacprzyk), Springer, 2021, 934, 421-451. ISBN 978-3-030-72283-8 SJR = 0.190 (2020)

Dissertations (in Bulgarian)

  1. (1) Pajeva I.K.: Microcomputer-based system for studying structure-activity relationships of antineoplastic drugs in /in vivo/ tumor models, PhD thesis in Biological Sciences, Sofia, 1989, 1-177.
  2. (2) Pajeva I.K.: In silico study of P-glycoprotein related multidrug resistance in tumors, DSci thesis in Biological Sciences, Sofia, 2007, 1-335.

Book Editing

  1. Almanach der Bulgarischen Humboldtianer. Herausgegeben von Dimo Platikanov, Ilza Pajeva und Lora Taseva, Craft House Bulgaria Ltd., 2011, pp. 296. ISBN 978-954-92223-3-3
  2. Bulgarian-German Scientific Cooperation: Past, Present, and Future. Ilza Pajeva, Radka Argirova, Krum Băčvarov, Dilyana Boteva and Nikolina Burneva, Editors. Faber Publishing House, 2016, pp. 239. ISBN 978-619-00-0517-9
  3. 25 years Humboldt Union in Bulgaria. Edited by Ilza Pajeva. Faber Publishing House, 2017, pp. 488. ISBN 978-619-00-0677-0

Comments are closed.